

**ABROCITINIB tablets (Cibinqo® ▼), TRALOKINUMAB injection (Adtralza® ▼) or
UPADACITINIB prolonged-release tablets (Rinvoq® ▼)
for treating moderate to severe atopic dermatitis**

**The Pan Mersey Area Prescribing Committee recommends the prescribing of
ABROCITINIB tablets (Cibinqo® ▼), TRALOKINUMAB injection (Adtralza® ▼) or
UPADACITINIB prolonged-release tablets (Rinvoq® ▼), by specialists only, for
treating moderate to severe atopic dermatitis in accordance with NICE TA814.**

RED

[NICE technology appraisal \(TA\) 814](#) (3 August 2022) recommends:

Abrocitinib and upadacitinib as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if:

- > the disease has not responded to at least one systemic immunosuppressant, or these are not suitable.
- > the companies provide abrocitinib and upadacitinib according to the commercial arrangement. ⁽¹⁾

Abrocitinib and upadacitinib are commissioned by NHS England for the treatment of young people aged 12 years and over.

Tralokinumab as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults, only if:

- > the disease has not responded to at least one systemic immunosuppressant, or these are not suitable
- > the company provides tralokinumab according to the commercial arrangement. ⁽¹⁾

Stop abrocitinib, upadacitinib or tralokinumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:

- > at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started **and**
- > at least a 4-point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started. ⁽¹⁾

Prescribing and monitoring must be retained by a specialist in the management of moderate to severe atopic dermatitis.

Costing information

Based on the NICE Resource Impact Template, NICE estimates the cost of implementing NICE TA814 as £44,000 per 100,000 in 2022/23 rising to £61,000 per 100,000 by 2026/27 when it is assumed that steady state has been reached. This is based on the NHS list price but the resource impact will be less once the PAS discounts are applied.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 814. [Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis \(TA814\)](#). 03 August 2022. Accessed 31 August 2022